Key Takeaways
- Synthomer's H1 2026 EBITDA from continuing operations rose 13.4% on a constant-currency basis (16.4% reported) to £96.7m, while underlying operating profit climbed 35.9% at constant currency to £48.6m.
- The board upgraded its full-year 2026 outlook to "slightly ahead of market expectations", citing a strong first-half EBITDA outturn and expectations of similar self-help progress in the second half.
- Statutory results remained loss-making — a total group loss for the period of £4.5m — as high finance costs and restructuring charges continued to weigh below the operating line.
- Net Debt of £671.3m and covenant Leverage of 4.9x remain the central risk; management targets 4.0--4.35x by year-end, excluding further disposals.
- The proposed £-denominated headline figures are supported, but "profit" refers to underlying operating profit at constant currency, not statutory profit.
Synthomer plc (LSE:SYNT), the Harlow-based maker of water-based polymers, adhesives and speciality chemicals, has spent the past two years fighting a reputation as one of the London market's more distressed mid-caps. Heavy debt taken on to fund the 2022 Acquisition of Eastman's adhesives business, collided with a brutal chemicals downturn, forcing a rights issue, Dividend suspension and a wholesale pivot towards higher-margin "speciality" end-markets. The interim results published on 4 August 2026 are the clearest evidence yet that the pivot is producing hard numbers rather than management rhetoric. The question for investors is whether an operational recovery can outrun a Balance Sheet that still carries almost as much net debt as the group's own Equity value implies.
Latest Company Development
For the six months to 30 June 2026, Synthomer reported Revenue from continuing operations of £954.3m, up 6.7% as reported and 5.1% at constant currency on the prior-year period's £894.4m. The headline profitability metrics were stronger still: EBITDA from continuing operations reached £96.7m, a 16.4% reported increase (13.4% at constant currency) from £83.1m, lifting the EBITDA Margin by 80 basis points to 10.1%. Underlying operating profit, the group's preferred measure of operational performance, jumped 35.9% at constant currency to £48.6m from £34.3m.
Crucially, management used the occasion to raise expectations. The company stated it had "upgraded its full year 2026 outlook to slightly ahead of market expectations", attributing the improvement to the strong first-half EBITDA outturn "led by underlying progress" and its expectation of "a broadly similar level of strategic growth and self-help progress recurring in H2 as in H1". Chief Executive Michael Willome framed the period as delivering "a strong performance so far in 2026, with the majority of progress coming from our sustained efforts to become a more speciality-focused company and our consistent work to 'control the controllables'". That upgrade — not merely a reaffirmation — is what distinguishes these results from the sequence of "in line" statements that preceded them.
Financial and Operational Position
The divisional detail explains where the momentum came from. Coatings & Construction Solutions was the standout, with EBITDA up 30.1% at constant currency to £46.0m and margins widening 220 basis points to 11.5%, driven by intumescent and high-performance industrial coatings — notably Demand tied to data-centre construction — with Asia and the United States the fastest-growing regions. Adhesive Solutions was more subdued, EBITDA rising 4.5% to £36.7m as intermittent reliability problems at facilities in Texas and the Netherlands capped output. Health & Protection and Performance Materials grew continuing EBITDA 5.9% to £24.9m, with Health & Protection volumes surging 13.5% as rivals' Supply networks were disrupted, partly offset by weaker foam and speciality vinyl demand.
Below the operating line, the picture is less flattering and warrants emphasis. Statutory operating profit was just £12.2m, and the group recorded a statutory pre-tax loss of £25.5m and a total loss for the period of £4.5m — a marked improvement on the £41.6m loss a year earlier, but a loss nonetheless. Net debt stood at £671.3m at the half-year, up from £575.0m at end-2025 on seasonal working-capital swings, leaving covenant leverage at 4.9x. Management refinanced in April 2026, pushing debt maturities out to February 2029, and now expects free Cash Flow to be positive for the full year. No Interim Dividend was declared.
What Could Drive the Shares Next
Three catalysts stand out. First, delivery against the upgraded guidance: with the second half expected to mirror the first, any further beat would reinforce the re-rating case. Second, deleveraging. The June agreement to sell the Acrylate Monomers Business to Mutares removes a cyclical, capital-intensive base-chemicals unit and is expected to complete around the end of the third quarter; further portfolio pruning could accelerate the path towards the 4.0--4.35x year-end leverage target. Third, sentiment normalisation — the shares, around 101p and valuing the group at roughly £166m, still price in considerable distress that the operational data increasingly contradicts. Should leverage fall convincingly, a valuation gap versus speciality-chemicals peers could begin to close.
Risks Investors Should Watch
The debt load remains the dominant risk. At 4.9x covenant leverage, Synthomer has limited headroom for a demand relapse, and interest costs continue to consume most of the operating profit the recovery is generating. Operational reliability is a second concern: the Texas and Netherlands issues that constrained Adhesive Solutions show how quickly production hiccups can erode the margin gains elsewhere. End-market cyclicality is a third — European construction and foam demand remain patchy, and the data-centre coatings tailwind, while genuine, concentrates growth in a single theme. Finally, the "upgrade" is measured against market expectations rather than an absolute target, so investors should treat it as directional rather than a guarantee of headline earnings.
Outlook
The strategic logic is now visible in the numbers: a narrower, higher-margin portfolio, disciplined cost control and disposals of cyclical Assets are lifting profitability faster than revenue. If management delivers a second half resembling the first and completes the Acrylate Monomers sale, Synthomer should exit 2026 with materially lower leverage and a genuine claim to speciality-chemicals status. The absence of a dividend and the still-elevated debt mean this remains a recovery play rather than an income or quality holding.
Final Take
Synthomer's first half validates the direction of travel. EBITDA up 13%, underlying operating profit up 36% and an outlook upgrade are exactly what a turnaround should look like at this stage. Yet with statutory losses persisting and leverage near five times, the Job is far from finished. The shares offer leverage to a successful deleveraging — and commensurate risk if it stalls.






Please wait processing your request...